Gilgamesh Pharma

News

Rumour partly confirmed as AbbVie acquires Gilgamesh drug

Reports of AbbVie's interest in Gilgamesh Pharma were true, as the companies have agreed a $1.2bn acquisition deal for a psychedelic depression drug.

News

Is AbbVie planning an epic Gilgamesh takeover?

AbbVie could be heading for its second acquisition in the space of a month, as rumours emerge of a $1bn bid for psychiatric drug developer Gilgamesh.

News

AbbVie takes option on Gilgamesh CNS drugs in $2bn deal

AbbVie has agreed to pay $65 million on an option deal with start-up Gilgamesh Pharma, lining up rights to neuroplastogen compounds that can improve neuroplasticity - the

Rumour partly confirmed as AbbVie acquires Gilgamesh drug

Is AbbVie planning an epic Gilgamesh takeover?

AbbVie takes option on Gilgamesh CNS drugs in $2bn deal

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Editor's Picks